Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background Prior work on the link between blood-based biomarkers and cognitive status has largely been based on dichotomous classifications rather than detailed neuropsychological functioning. The current project was designed to create serum-based biomarker algorithms that predict neuropsychological test performance. Methods A battery of neuropsychological measures was administered. Random forest analyses were utilized to create neuropsychological test-specific biomarker risk scores in a training set that were entered into linear regression models predicting the respective test scores in the test set. Serum multiplex biomarker data were analyzed on 108 proteins from 395 participants (197 Alzheimer patients and 198 controls) from the Texas Alzheimer's Research and Care Consortium. Results The biomarker risk scores were significant predictors (p Conclusions Our findings provide proof of concept for a novel area of scientific discovery, which we term 'molecular neuropsychology'.

What this study adds

Evidence grade: Low

The record lists 395 participants. This early work used blood proteins to build scores that predicted performance on specific neuropsychological tests in a sample of 395 people. The authors describe it as proof of concept for a new approach they call 'molecular neuropsychology,' not a ready test for patients.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

O'Bryant, S. E., Xiao, G., Barber, R., Cullum, C. M., Weiner, M., Hall, J., et al. (2014). Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dementia and geriatric cognitive disorders. https://doi.org/10.1159/000345605

Vancouver

O'Bryant SE, Xiao G, Barber R, Cullum CM, Weiner M, Hall J, et al. Molecular neuropsychology: creation of test-specific blood biomarker algorithms. Dementia and geriatric cognitive disorders. 2014. doi:10.1159/000345605. PMID: 24107792.

BibTeX

@article{obryant2014-24107792,
  author  = {O'Bryant, S. E. and Xiao, G. and Barber, R. and Cullum, C. M. and Weiner, M. and Hall, J. and Edwards, M. and Grammas, P. and others},
  title   = {{Molecular neuropsychology: creation of test-specific blood biomarker algorithms}},
  journal = {Dementia and geriatric cognitive disorders},
  year    = {2014},
  doi     = {10.1159/000345605},
  pmid    = {24107792},
  url     = {https://doi.org/10.1159/000345605}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This early work used blood proteins to build scores that predicted performance on specific neuropsychological tests in a sample of 395 people. The authors describe it as proof of concept for a new approach they call 'molecular neuropsychology,' not a ready test for patients.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 41 of 100.41 of 100 points earned59 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Dementia and geriatric cognitive disorders)
Journal's citation record 1 / 4 Dementia and Geriatric Cognitive Disorders: journal h-index 149 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2014 — within 20 year(s) of the newest study here
Sample size 2 / 4 395 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 16 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.1 citations a year over 14 year(s) since 2014
Impact for its field and year 2 / 6 Cited 1.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Ramon R. Diaz-Arrastia: h-index 105 (OpenAlex, whole career)
Institution's track record 2 / 3 University of North Carolina at Chapel Hill: institution h-index 1,674 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24107792)
Free to read 0 / 2 Behind a paywall — scores zero
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Biomarkers from nearby years

Also in Biomarkers

137 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →